Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $70.77 USD
Change Today -0.46 / -0.65%
Volume 6.8M
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$71.29
Previous Close
$71.23
Day High
$71.51
Day Low
$70.74
52 Week High
07/21/15 - $71.60
52 Week Low
08/6/14 - $51.37
Market Cap
123.8B
Average Volume 10 Days
8.2M
EPS TTM
$3.60
Shares Outstanding
1.8B
EX-Date
07/13/15
P/E TM
19.6x
Dividend
$2.04
Dividend Yield
2.73%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

28,000 Employees
Last Reported Date: 07/24/15
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (ABBV) Key Developments

Abbvie Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year of 2015

AbbVie Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of $5,475 million against $4,926 million a year ago. Operating earnings were $1,852 million compared to $1,515 million a year ago. Earnings before income tax expense was $1,678 million compared to $1,433 million a year ago. Net earnings were $1,366 million against $1,098 million a year ago. Diluted earnings per share were $0.83 compared to $0.68 a year ago. Non-GAAP pre-tax earnings were $2,275 million compared to $1,710 million a year ago. Non-GAAP after tax earnings were $1,776 million or $1.08 per diluted share compared to $1,330 million or $0.82 per diluted share a year ago. Second-quarter sales growth was driven by the continued strength of HUMIRA and other promoted products. For the six months period, the company reported net revenues of $10,515 million against $9,489 million a year ago. Operating earnings were $3,539 million compared to $2,866 million a year ago. Earnings before income tax expense was $3,074 million compared to $2,719 million a year ago. Net earnings were $2,388 million against $2,078 million a year ago. Diluted earnings per share were $1.47 compared to $1.29 a year ago. Non-GAAP pre-tax earnings were $4,235 million compared to $3,190 million a year ago. Non-GAAP after tax earnings were $3,300 million or $2.03 per diluted share compared to $2,480 million or $1.53 per diluted share a year ago. The company is confirming its adjusted diluted earnings-per-share guidance for the full-year 2015 of $4.10 to $4.30. The company’s 2015 adjusted diluted earnings-per-share guidance excludes $0.84 per share of intangible asset amortization expense, deal costs, integration, and other specified items, and includes $0.20 of dilution related to the Pharmacyclics acquisition. The company’s diluted earnings-per-share guidance is $3.26 to $3.46 on a GAAP basis.

C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

C2N Diagnostics and AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study of C2N-8E12 in patients with PSP. C2N-8E12 is a humanized antibody targeting the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer's disease (AD). The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose, multicenter study that will evaluate the safety, tolerability and pharmacokinetics of C2N-8E12 in an estimated 32 subjects with PSP.

Biotest Announces Termination of Tregalizumab Collaboration with AbbVie

Biotest AG and AbbVie Inc. have terminated their collaboration for the development and commercialization of Tregalizumab, which is intended for treatment of rheumatoid arthritis, or RA. AbbVie has exercised its rights to opt-out of the worldwide license, development and commercialisation agreement signed in June 2011. Upon the effective date of termination, AbbVie will return all rights granted under the agreement at no cost to Biotest. Tregalizumab is an investigational humanised anti-CD4 monoclonal antibody, inducing selective activation of regulatory T-cells. As announced on April 24, 2015, the Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with moderate to severe rheumatoid arthritis (RA) did not meet its primary endpoint.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $70.77 USD -0.46

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $171.47 USD -1.27
Bristol-Myers Squibb Co $64.89 USD +0.23
Eli Lilly & Co $85.09 USD -0.59
Medtronic PLC $77.88 USD +0.41
Novo Nordisk A/S kr400.00 DKK +7.00
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 55.5x
Price/Sales 5.5x
Price/Book 82.4x
Price/Cash Flow 54.5x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.